C O R E D : The staff of the Biostastics Core will be responsible for providing biostatistical support to the research related to therapeutic response and recurrence of this program. The Biostatistical Core is under the supervision of Dr. Timothy D. Johnson of the Biostatistics Department in the University of Michigan School of Public Health. The core provides assistance in the design, analysis and interpretation of preclinical and clinical experiments of the program project. Core personnel will interact with project investigators to ensure that appropriate designs and methods of analysis are used. Design issues involve selection of dose, randomization, timing of measurements, number of animals or patients. For analysis of data, the core will ensure that efficient methods are used. Standard graphical, group comparison and correlation methods of analysis will be used for initial investigation of the experimental data. Mixed model methods will be used for efficient use of the data in experiments involving repeated measures. Core personnel are experienced in the design and analysis of both animal and clinical data. This will ensure that all data will be collected efficiently and analyzed appropriately. Although these tasks are distinct from thise described in Core C, a close interaction between Cores D and C will be maintained so that data analysis of overiapping experiments can be analyzed in an efficient and productive manner. Similarly Core B will serve as a source of a majority of imaging data for subsequent analysis using statistical modeling and thus close interaction with this Core will also be key to the success of the program.

Public Health Relevance

Overall, this Core will provide the basis for determining the efficacy of new combinations of moleculariy targeted therapies for the treatment of malignant brain tumors. In addition, imaging biomarkers for early assessment of treatment response will be identified and validated which will lead to individualization of patient treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA085878-11
Application #
8745107
Study Section
Special Emphasis Panel (ZCA1-RPRB-W)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
11
Fiscal Year
2014
Total Cost
$172,766
Indirect Cost
$88,258
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Galbán, C J; Hoff, B A; Chenevert, T L et al. (2016) Diffusion MRI in early cancer therapeutic response assessment. NMR Biomed :
Chen, Daiqin; Dougherty, Casey A; Yang, Dongzhi et al. (2016) Radioactive Nanomaterials for Multimodality Imaging. Tomography 2:3-16
Masch, William R; Wang, Page I; Chenevert, Thomas L et al. (2016) Comparison of Diffusion Tensor Imaging and Magnetic Resonance Perfusion Imaging in Differentiating Recurrent Brain Neoplasm From Radiation Necrosis. Acad Radiol 23:569-76
Van Dort, Marcian E; Hong, Hao; Wang, Hanxiao et al. (2016) Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K). J Med Chem 59:2512-22
Ross, Brian D (2016) Demonstration of an Inline Publication Image Viewer: The Future of Radiological Publishing. Tomography 2:1-2
Aryal, Madhava P; Chenevert, Thomas L; Cao, Yue (2016) Impact of uncertainty in longitudinal T1 measurements on quantification of dynamic contrast-enhanced MRI. NMR Biomed 29:411-9
Nyati, Shyam; Chator, Areeb; Schinske, Katerina et al. (2016) A Requirement for ZAK Kinase Activity in Canonical TGF-β Signaling. Transl Oncol 9:473-481
Ceccarelli, Michele; Barthel, Floris P; Malta, Tathiane M et al. (2016) Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell 164:550-63
Tang, Ming; Verhaak, Roel Gw (2016) A Molecular Take on Malignant Rhabdoid Tumors. Trends Cancer 2:217-218
Lemasson, Benjamin; Wang, Hanxiao; Galbán, Stefanie et al. (2016) Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model. Neoplasia 18:82-9

Showing the most recent 10 out of 140 publications